Search

Your search keyword '"Gelmon, K."' showing total 6 results
Start Over Author "Gelmon, K." Journal british journal of cancer
6 results on '"Gelmon, K."'

2. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

Author

Wishart, G C, primary, Bajdik, C D, additional, Dicks, E, additional, Provenzano, E, additional, Schmidt, M K, additional, Sherman, M, additional, Greenberg, D C, additional, Green, A R, additional, Gelmon, K A, additional, Kosma, V-M, additional, Olson, J E, additional, Beckmann, M W, additional, Winqvist, R, additional, Cross, S S, additional, Severi, G, additional, Huntsman, D, additional, Pylkäs, K, additional, Ellis, I, additional, Nielsen, T O, additional, Giles, G, additional, Blomqvist, C, additional, Fasching, P A, additional, Couch, F J, additional, Rakha, E, additional, Foulkes, W D, additional, Blows, F M, additional, Bégin, L R, additional, van't Veer, L J, additional, Southey, M, additional, Nevanlinna, H, additional, Mannermaa, A, additional, Cox, A, additional, Cheang, M, additional, Baglietto, L, additional, Caldas, C, additional, Garcia-Closas, M, additional, and Pharoah, P D P, additional

Published
2012
Full Text
View/download PDF

3. Erratum: BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Author

Dawson, S-J, primary, Makretsov, N, additional, Blows, F M, additional, Driver, K E, additional, Provenzano, E, additional, Le Quesne, J, additional, Baglietto, L, additional, Severi, G, additional, Giles, G G, additional, McLean, C A, additional, Callagy, G, additional, Green, A R, additional, Ellis, I, additional, Gelmon, K, additional, Turashvili, G, additional, Leung, S, additional, Aparicio, S, additional, Huntsman, D, additional, Caldas, C, additional, and Pharoah, P, additional

Published
2010
Full Text
View/download PDF

4. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Author

Dawson, S-J, primary, Makretsov, N, additional, Blows, F M, additional, Driver, K E, additional, Provenzano, E, additional, Le Quesne, J, additional, Baglietto, L, additional, Severi, G, additional, Giles, G G, additional, McLean, C A, additional, Callagy, G, additional, Green, A R, additional, Ellis, I, additional, Gelmon, K, additional, Turashvili, G, additional, Leung, S, additional, Aparicio, S, additional, Huntsman, D, additional, Caldas, C, additional, and Pharoah, P, additional

Published
2010
Full Text
View/download PDF

5. TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.

Author

Bartlett, J M S, Nielsen, T O, Gao, D, Gelmon, K A, Quintayo, M A, Starczynski, J, Han, L, Burnell, M J, Levine, M N, Chen, B E, Shepherd, L E, and Chapman, J W

Subjects
TAXANES, IMMUNOHISTOCHEMISTRY, BREAST cancer diagnosis, WNT genes, BIOMARKERS, CELLULAR signal transduction, CLINICAL trials
Abstract

Background:TLE3, a nuclear transcriptional repressor downstream of WNT signalling pathways, has been hypothesised as predictive of benefit from adjuvant taxane.Methods:MA.21 tissue microarrays were constructed from 1097 out of 2104 (52%) patients. TLE3 staining by immunohistochemistry used validated methodology. Continuous TLE3+ (percentage of cells staining positive) was assessed with both visual and automated scoring. The primary objective was to test the predictive effect of TLE3 on relapse-free survival using the MA.21 EC/T and CEF arms and the previously defined cut-point of 30% of cells staining positive in ⩾1 core/tumour.Results:MA.21 patients had 83.2% TLE3 positive (TLE3+) tumours by visual score and 80.6% TLE3+ by automated image analysis while the previously observed rate of TLE3+ cases was 58.6%. TLE3 expression was significantly associated with ER expression (91.2% of ER-positive tumours were TLE3+; P<0.0001). At median 8-year follow-up, there was no evidence of a predictive effect of TLE3 expression with respect to taxane benefit using the established 30% or exploratory quartile cut-points.Conclusions:Proportionately more MA.21 patient tumours than expected were TLE3+. The pre-specified TLE3+ cut-point of 30% was not predictive of taxane benefit. TLE3 expression does not represent a viable biomarker for taxane benefit in breast cancer. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results